Integer (ITGR) Expected to Release Earnings on Thursday

by · The Cerbat Gem

Integer (NYSE:ITGR – Get Free Report) is expected to announce its Q3 2026 results before the market opens on Thursday, October 22nd. Analysts expect the company to post earnings of $1.68 per share and revenue of $456.91 million for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, October 29, 2026 at 9:00 AM ET.

Integer (NYSE:ITGR – Get Free Report) last announced its quarterly earnings data on Monday, August 3rd. The medical equipment provider reported $1.60 earnings per share for the quarter, topping the consensus estimate of $1.38 by $0.22. Integer had a return on equity of 12.79% and a net margin of 6.97%. The company had revenue of $464.11 million during the quarter, compared to analyst estimates of $451.07 million. During the same quarter last year, the firm posted $1.55 EPS. The firm’s revenue for the quarter was down 2.6% on a year-over-year basis. On average, analysts expect Integer to post $6.09 EPS for the current fiscal year and $6.71 EPS for the next fiscal year.

Integer Trading Down 0.0%

Shares of Integer stock opened at $126.72 on Wednesday. The stock has a market capitalization of $4.31 billion, a P/E ratio of 34.62, a P/E/G ratio of 2.41 and a beta of 0.58. Integer has a 52-week low of $62.00 and a 52-week high of $126.83. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.41 and a current ratio of 3.73. The stock’s 50-day simple moving average is $126.03 and its 200 day simple moving average is $105.13.

Insider Buying and Selling at Integer

In other news, insider Kirk K. Thor sold 19,773 shares of the company’s stock in a transaction on Monday, September 14th. The shares were sold at an average price of $126.25, for a total value of $2,496,341.25. Following the transaction, the insider owned 18,920 shares of the company’s stock, valued at approximately $2,388,650. This represents a 51.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Andrew Senn sold 9,408 shares of the stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $126.30, for a total value of $1,188,230.40. Following the completion of the sale, the insider owned 5,405 shares in the company, valued at $682,651.50. This trade represents a 63.51% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 40,948 shares of company stock valued at $5,169,920. Insiders own 1.10% of the company’s stock.

Analysts Set New Price Targets

ITGR has been the subject of a number of research reports. Raymond James Financial lowered shares of Integer from a “moderate buy” rating to a “hold” rating in a research report on Monday, August 3rd. Piper Sandler lowered shares of Integer from an “overweight” rating to a “hold” rating and set a $127.00 price target on the stock. in a research report on Monday, August 3rd. Truist Financial lowered shares of Integer from a “buy” rating to a “hold” rating and boosted their price target for the company from $110.00 to $127.00 in a research report on Monday, August 3rd. Oppenheimer cut shares of Integer from an “outperform” rating to a “market perform” rating in a research note on Monday, August 3rd. Finally, Freedom Capital cut shares of Integer from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 4th. One equities research analyst has rated the stock with a Buy rating and thirteen have issued a Hold rating to the company’s stock. According to MarketBeat, Integer currently has a consensus rating of “Hold” and an average price target of $109.86.

Get Our Latest Analysis on Integer

About Integer

(Get Free Report)

Integer Holdings Corporation (NYSE: ITGR) is a global medical device and advanced energy technology company. It partners with original equipment manufacturers to design and manufacture components, subassemblies and finished products used in minimally invasive and implantable medical devices.

Its medical technologies include batteries and power systems for pacemakers, implantable cardioverter-defibrillators, neurostimulators and drug-delivery systems, as well as catheter and guidewire components, coated wire, electrodes and other products used in cardiovascular, neuromodulation and other medical applications.

Integer also develops specialty batteries and power solutions for markets such as energy, aerospace and defense.

Featured Stories